Pédiatrique divers

  • Accueil
  • Pédiatrique divers
  • ABLE 2.0 /? PTCTC GVH 1901

TITRE (EN) Biomarker Verification in Pediatric Chronic Graft-Versus-Host Disease: Applied Biomarkers to Minimize Long Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) / Pediatric Transplantation & Cellular Therapy Consortium (PTCTC)
PROTOCOLE ID ABLE 2.0 /? PTCTC GVH 1901
CLINICAL TRIAL.gov ID NCT04372524
TYPE(S) DE CANCER Pédiatrique divers
PHASE Autres
TYPE D'ÉTUDE
INSTITUTION CENTRE UNIVERSITAIRE DE SANTE MCGILL
1001 boul. Décarie
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) David Mitchell
COORDONATEUR(RICE) Samira Mezziani
mch.rho@muhc.mcgill.ca
514-412-4400 poste 22930
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Any indication for allogeneic hematopoietic stem cell transplant (malignant or non-malignant)
  • Age 0 - 24.99 years at the time of transplant (on day 0)
  • Any conditioning regimen (including myeloablative or reduced-toxicity/reduced-intensity)
  • Any graft source (bone marrow, peripheral blood, cord blood)
  • Any graft-versus-host disease prophylaxis strategy, including serotherapy such as ATG or alemtuzumab
  • Haploidentical transplants, including post-transplant cyclophosphamide and alpha-beta TCR depletion, are allowed
CRITÈRES D'EXCLUSION (EN)
  • Second or greater allogeneic transplant
  • Weight 7 kg or less
  • Pure CD34+ selected haploidentical stem cell transplant (not including CD34 enrichment used in alpha-beta TCR depleted haploidentical transplants, which is allowed)
  • Inability of a center to follow a patient for the development of late-acute and chronic GVHD until 1-year post-transplant (referral sites who transplant patients from outside institutions should not enroll participants if sending back to the referring site early, such that long-term follow up, blood, and data collection cannot be assured).